Fluvoxamine, an antidepressant also known as ‘Luvox’, shows promise as a COVID-19 therapeutic by preventing severe illness. The drug may have the ability to reduce inflammation and blood-clotting associated with COVID-19. Enable Biosciences CEO Dr. David Seftel observes the effects of fluvoxamine in Golden Gate Fields racetrack employees who were recently diagnosed with COVID-19.
Fluvoxamine: A Potential Treatment Candidate For Covid-19
Previous
Previous
Covid-19 Serosurveillance: Antibody Detection After Infection And Vaccination
Next
Next